SCHEMBL25839666

SCHEMBL25839666

CCOC(=O)c1cnn2c(N(Cc3ccccc3)Cc3ccccc3)c(-c3ccc(Cl)cc3F)c(Cl)nc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNA2 P20248 1/20 0.49
CDK2 P24941 1/20 0.49
SMN1; SMN2 Q16637 6/20 0.45
KDM4E B2RXH2 6/20 0.45
HSD17B10 Q99714 6/20 0.45
HPGD P15428 5/20 0.45
ALDH1A1 P00352 5/20 0.45
NPC1 O15118 4/20 0.45
RAB9A P51151 4/20 0.45
CASP1 P29466 2/20 0.44
CASP7 P55210 2/20 0.44
TSHR P16473 2/20 0.44
KMT2A Q03164 1/20 0.43
LMNA P02545 1/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 3/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
GLA P06280 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25170456 0.93 KDM4E (0.46) CCNA2CDK2SMN1; SMN2KDM4EHSD17B10
SCHEMBL25839704 0.85 ALDH1A1 (0.54) CCNA2CDK2SMN1; SMN2KDM4EHSD17B10
SCHEMBL25177366 0.83 SMN1; SMN2 (0.50) CCNA2CDK2SMN1; SMN2KDM4EHSD17B10
SCHEMBL25117946 0.77 KDM4E (0.48) CCNA2CDK2SMN1; SMN2KDM4EHSD17B10
SCHEMBL30184379 0.77 KDM4E (0.48) CCNA2CDK2SMN1; SMN2KDM4EHSD17B10
SCHEMBL25177371 0.76 KDM4E (0.54) CCNA2CDK2SMN1; SMN2KDM4EHSD17B10
SCHEMBL25117818 0.76 KDM4E (0.50) CCNA2CDK2SMN1; SMN2KDM4EHSD17B10
SCHEMBL20678782 0.75 KDM4E (0.54) CCNA2CDK2SMN1; SMN2KDM4EHSD17B10
SCHEMBL25117816 0.74 KDM4E (0.52) CCNA2CDK2SMN1; SMN2KDM4EHSD17B10
SCHEMBL28994151 0.73 HSD17B10 (0.38) CCNA2CDK2SMN1; SMN2KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219978-A1 COMPOUND HAVING MACROCYCLIC STRUCTURE AND USE THEREOF SCINNOHUB PHARMACEUTICAL CO., LTD (CN) 2023-07-13 US disclosed
US-20230219978-A1 COMPOUND HAVING MACROCYCLIC STRUCTURE AND USE THEREOF SCINNOHUB PHARMACEUTICAL CO., LTD (CN) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219978-A1 COMPOUND HAVING MACROCYCLIC STRUCTURE AND USE THEREOF BTK, SRC, YES1 CCNA2 1362/4885CDK2 236/4885SMN1; SMN2 1720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.